Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.

Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFN alpha-2a) and interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced colorectal cancer. This phase II study was designed to evaluate the anti-tumour activity and toxicity of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Goey, S. H., Gratama, J. W., Primrose, J. N., Ward, U., Mertelsmann, R. H., Osterwalder, B., Verweij, J., Stoter, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074801/
https://www.ncbi.nlm.nih.gov/pubmed/8980407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074801/
https://www.ncbi.nlm.nih.gov/pubmed/8980407

Ejemplares similares